Development of ribozyme-based gene-inactivations; the example of the hepatitis delta virus ribozyme.

The development of gene-inactivation systems is an active and important field for both functional genomics and gene therapy. Towards this end, ribozymes (i.e. RNA enzymes), that specifically recognize and subsequently catalyze the cleavage of other target RNA molecules, are attractive molecular tools. Ribozymes represent an interesting alternative to the RNA interference (RNAi) approach for gene inactivation, especially given the fact that RNAi seems to trigger an immunological response and has demonstrated off-target effects. However, the design and optimization of a ribozyme-based gene-inactivation system is not a straightforward procedure. Several aspects need to be considered in the experimental design in order to provide a suitable suppression system. In this review we present the advances in this domain made available from work using the hepatitis delta virus (HDV) ribozyme as a cis-acting RNA motif in molecular biology, as well as a trans-acting molecular scissor for the development of a gene-inactivation system. This HDV ribozyme technology possesses several unique features that are all related to the fact that it is the only catalytic cleaving RNA motif that has been discovered in humans.

Identification of compounds that inhibit the interaction between core and surface protein of hepatitis B virus.

Specific interactions of the human hepatitis B virus (HBV) surface proteins with the core protein of nucleocapsid are critical for the envelopment of virus particles, and inhibition of this process may prevent the production of infectious virus. A modified enzyme-linked immunosorbent assay (ELISA), which measured the interaction between the core protein and PreS region of the surface protein, was used to screen a chemical library for compounds that would block this interaction. Few inhibitory compounds were identified from a chemical library consisting of 5600 compounds. Among them, two compounds inhibited the production of HBV particles from transiently HBV-producing HuH7 cells. The IC50 values of these compounds for inhibition of HBV production in HuH7 cells were in the micromolar concentration range. These results indicate that compounds that prevent the interaction between the core protein and PreS region of the surface protein may possibly be useful as anti-HBV agents.

Exploring the active site of chorismate mutase by combinatorial mutagenesis and selection: the importance of electrostatic catalysis.

Chorismate mutase (EC 5.4.99.5) catalyzes the intramolecular rearrangement of chorismate to prephenate. Arg-90 in the active site of the enzyme from Bacillus subtilis is in close proximity to the substrate's ether oxygen and may contribute to efficient catalysis by stabilizing the presumed dipolar transition state that would result upon scission of the C--O bond. To test this idea, we have developed a novel complementation system for chorismate mutase activity in Escherichia coli by reengineering parts of the aromatic amino acid biosynthetic pathway. The codon for Arg-90 was randomized, alone and in combination with that for Cys-88, and active clones were selected. The results show that a positively charged residue either at position 88 (Lys) or 90 (Arg or Lys) is essential. Our data provide strong support for the hypothesis that the positive charge is required for stabilization of the transition state of the enzymatic chorismate rearrangement. The new selection system, in conjunction with combinatorial mutagenesis, renders the mechanism of the natural enzyme(s) accessible to further exploration and opens avenues for the improvement of first generation catalytic antibodies with chorismate mutase activity.